The China Mail - Study shows how fast kilos return after ending weight-loss drugs

USD -
AED 3.6725
AFN 66.000282
ALL 82.619619
AMD 381.390629
ANG 1.790403
AOA 916.999757
ARS 1463.486502
AUD 1.492983
AWG 1.80125
AZN 1.702768
BAM 1.675498
BBD 2.014915
BDT 122.246875
BGN 1.666695
BHD 0.376931
BIF 2962
BMD 1
BND 1.284599
BOB 6.937407
BRL 5.3881
BSD 1.000433
BTN 89.8933
BWP 13.396785
BYN 2.953067
BYR 19600
BZD 2.012011
CAD 1.38686
CDF 2265.000294
CHF 0.799125
CLF 0.022865
CLP 896.990057
CNY 6.983749
CNH 6.98228
COP 3715.26
CRC 497.305725
CUC 1
CUP 26.5
CVE 95.049788
CZK 20.83895
DJF 177.720333
DKK 6.410702
DOP 63.650028
DZD 130.043952
EGP 47.279903
ERN 15
ETB 155.374956
EUR 0.857905
FJD 2.27745
FKP 0.742335
GBP 0.74445
GEL 2.684971
GGP 0.742335
GHS 10.720271
GIP 0.742335
GMD 73.483536
GNF 8739.999719
GTQ 7.668156
GYD 209.295851
HKD 7.792049
HNL 26.429914
HRK 6.463202
HTG 131.012298
HUF 330.440497
IDR 16812.85
ILS 3.169125
IMP 0.742335
INR 89.90595
IQD 1310
IRR 42125.000158
ISK 126.289901
JEP 0.742335
JMD 158.374704
JOD 0.709034
JPY 156.913499
KES 129.000448
KGS 87.443504
KHR 4025.49364
KMF 422.501945
KPW 899.997826
KRW 1452.103721
KWD 0.30734
KYD 0.833722
KZT 509.90538
LAK 21600.000192
LBP 89550.000307
LKR 309.116376
LRD 179.500028
LSL 16.459534
LTL 2.95274
LVL 0.60489
LYD 5.415025
MAD 9.214504
MDL 16.707002
MGA 4594.99986
MKD 52.795244
MMK 2099.899971
MNT 3559.878067
MOP 8.029932
MRU 39.719744
MUR 46.529731
MVR 15.450127
MWK 1736.00021
MXN 17.980275
MYR 4.0655
MZN 63.895387
NAD 16.459992
NGN 1424.840207
NIO 36.785004
NOK 10.08232
NPR 143.829725
NZD 1.739625
OMR 0.384503
PAB 1.000433
PEN 3.363503
PGK 4.26825
PHP 59.169554
PKR 280.074991
PLN 3.61339
PYG 6754.846613
QAR 3.64125
RON 4.365298
RSD 100.627986
RUB 80.500403
RWF 1455
SAR 3.750118
SBD 8.126887
SCR 12.567129
SDG 601.547361
SEK 9.22244
SGD 1.2853
SHP 0.750259
SLE 24.075981
SLL 20969.503664
SOS 571.502091
SRD 38.290502
STD 20697.981008
STN 21.35
SVC 8.753496
SYP 11059.574895
SZL 16.460201
THB 31.430027
TJS 9.298763
TMT 3.51
TND 2.891502
TOP 2.40776
TRY 43.135702
TTD 6.792656
TWD 31.559201
TZS 2497.498731
UAH 43.100844
UGX 3598.062187
UYU 38.961873
UZS 12010.000038
VES 311.541545
VND 26270
VUV 120.537528
WST 2.773898
XAF 561.948616
XAG 0.013057
XAU 0.000223
XCD 2.70255
XCG 1.802972
XDR 0.69877
XOF 560.507894
XPF 102.514885
YER 238.449916
ZAR 16.527405
ZMK 9001.202677
ZMW 19.833033
ZWL 321.999592
  • SCS

    0.0200

    16.14

    +0.12%

  • RBGPF

    -0.2200

    81.57

    -0.27%

  • CMSD

    -0.1000

    23.5

    -0.43%

  • NGG

    0.0900

    79.48

    +0.11%

  • CMSC

    0.0100

    23.01

    +0.04%

  • BTI

    0.5000

    53.79

    +0.93%

  • BP

    0.4600

    34.13

    +1.35%

  • GSK

    -0.4000

    50.22

    -0.8%

  • BCE

    0.4200

    23.75

    +1.77%

  • RIO

    -0.6900

    84.19

    -0.82%

  • RELX

    0.1700

    42.35

    +0.4%

  • AZN

    -1.1500

    94.01

    -1.22%

  • BCC

    4.5600

    78.03

    +5.84%

  • JRI

    0.1000

    13.74

    +0.73%

  • RYCEF

    0.1500

    17.15

    +0.87%

  • VOD

    -0.1550

    13.82

    -1.12%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: © AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

Y.Parker--ThChM